Phase I trial of CTP 298 in patients with HIV infections.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2013
At a glance
- Drugs CTP 298 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 27 Jun 2013 Status changed from planning to discontinued, based on the June 2013 product pipeline of Concert Pharmaceuticals. It appears that the development of this agent has been discontinued.
- 21 Jun 2011 New trial record